日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

In Situ Vaccination with Poly-ICLC Combined with Systemic Nivolumab for the Treatment of Unresectable Hepatocellular Carcinoma

采用聚肌胞苷酸环化物(Poly-ICLC)原位疫苗联合全身性纳武利尤单抗治疗不可切除的肝细胞癌

Liang, Ja-Der; Liang, Po-Chin; Shun, Chia-Tung; Chen, Chien-Hung; Wu, Yao-Ming; Hsu, Yu-Chen; Lee, Ying-Te; Yang, Pei-Ming; Huang, Guan-Tarn; Salazar, Andres M; Lee, Hsuan-Shu; Sheu, Jin-Chuan; Weng, Meng-Tzu

Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial

靶向溶瘤腺病毒 OBP-301 治疗难治性晚期肝癌的安全性和剂量递增:I 期临床试验

Heo, Jeong; Liang, Ja-Der; Kim, Chang Won; Woo, Hyun Young; Shih, I-Lun; Su, Tung-Hung; Lin, Zhong-Zhe; Yoo, So Young; Chang, Stanley; Urata, Yasuo; Chen, Pei-Jer

Prospective assessment of diagnostic efficacy and safety of Sonazoid(TM) and SonoVue(®) ultrasound contrast agents in patients with focal liver lesions

对 Sonazoid(TM) 和 SonoVue(®) 超声造影剂在局灶性肝脏病变患者中的诊断效果和安全性进行前瞻性评估

Lv, Ke; Zhai, Hongyan; Jiang, Yuxin; Liang, Ping; Xu, Hui-Xiong; Du, Lianfang; Chou, Yi-Hong; Xie, Xiaoyan; Luo, YuKun; Lee, Young Joon; Lee, Jae Young; Hu, Bing; Luo, Baoming; Wang, Yi; Luan, Ying; Kalli, Christina; Chen, Kun; Wang, Wenping; Liang, Ja-Der

Safety of Perfluorobutane (Sonazoid) in Characterizing Focal Liver Lesions

全氟丁烷(Sonazoid)在局灶性肝脏病变鉴别诊断中的安全性

Chou, Yi-Hong; Liang, Ja-Der; Wang, Shen-Yung; Hsu, Shih-Jer; Hu, Jui-Ting; Yang, Sien-Sing; Wang, Hsin-Kai; Lee, Tien-Ying; Tiu, Chui-Mei

Brain isoform glycogen phosphorylase as a novel hepatic progenitor cell marker

脑亚型糖原磷酸化酶作为一种新的肝祖细胞标记物

Yu-Wen Huang, Chien-Chang Chiu, Ja-Der Liang, Ling-Ling Chiou, Guan-Tarn Huang, Ming-Jiun Yu, Hsuan-Shu Lee

Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study

接受单疗程经动脉化疗栓塞治疗的肝细胞癌患者的生活质量及其相关因素:一项纵向研究

Shun, Shiow-Ching; Chen, Chien-Hung; Sheu, Jin-Chuan; Liang, Ja-Der; Yang, Jyh-Chin; Lai, Yeur-Hur